TY - JOUR T1 - Doxazosin was associated with more stroke and cardiovascular disease events than chlorthalidone in high risk hypertension JF - Evidence Based Medicine JO - Evid Based Med SP - 172 LP - 172 DO - 10.1136/ebm.5.6.172 VL - 5 IS - 6 A2 - , Y1 - 2000/11/01 UR - http://ebm.bmj.com/content/5/6/172.abstract N2 - (2000) JAMA 283, 1967. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. Apr 19;. :. –75.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In high risk hypertensive patients, is doxazosin (an α-adrenergic blocker) or chlorthalidone (a diuretic) more effective in reducing cardiovascular disease (CVD) events? Randomised (allocation concealed*), blinded (clinicians and patients),* controlled trial with median 3.3 year follow up. 625 centres in the US and Canada. 24 335 patients who were ≥55 years of age (mean age 67 y, 53% men, 49% white non-Hispanic), had systolic blood pressure (BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg, took medication for hypertension, and had ≥1 other risk factor for coronary heart disease (CHD). {Exclusion criteria included myocardial infarction (MI), stroke, or angina pectoris in the past 6 months; congestive heart failure (CHF) or ejection fraction <35%; or serum creatinine concentration ≥177 μmol/l.}† 97% of patients were included in the analysis. Patients were allocated … ER -